Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A PCAB-accredited dual operator — a 503A pharmacy in Ocala, FL plus a 503B outsourcing facility in Dyersburg, TN — strong in HRT/BHRT, weight, and peptides. Not the same company as Wells Pharma of Houston.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
Wells Pharmacy Network runs both a patient-specific 503A pharmacy and an FDA-registered 503B outsourcing facility. One disambiguation up front: this is Wells Pharmacy Network, LLC — a different company from Wells Pharma of Houston, LLC (a separate Houston hospital-injectables 503B).
The legal entity is Wells Pharmacy Network, LLC. It operates a 503A pharmacy in Ocala, FL and a 503B outsourcing facility in Dyersburg, TN — the latter appears on the FDA 503B list as “Wells Pharmacy, Inc.,” Dyersburg, TN (initial registration 2016-06-07) [1]. We independently confirmed PCAB accreditation for the Ocala 503A in ACHC’s own directory (Wells Pharmacy Network, LLC, Ocala, FL) [2]. The site also displays PCAB, PCCA, and Alliance for Pharmacy Compounding logos, and says it ships nationwide [3].
On-audience: wellness/anti-aging, weight management, sexual wellness, HRT/BHRT (including bioidentical hormone pellets), thyroid/adrenal, and longevity, plus peptides such as sermorelin [3]. Its public “trending” mix leans HRT/sermorelin/NAD+/thyroid; compounded GLP-1 is offered under weight management.
We found no FDA warning letter for Wells Pharmacy Network in public sources. The Dyersburg 503B facility carries an FDA-list footnote indicating a prior inspection resulting in a 483/action, with its most recent inspection logged 2026-04-09 [1]; we did not retrieve a specific dated document beyond that flag, so we don’t assert specifics. A Form 483 documents inspection observations, not a final finding. Dated to our review; status can change.
A well-established dual 503A/503B operator with PCAB accreditation independently confirmed on the 503A side — a good “how a dual-status compounder works” example, strong in HRT/BHRT and peptides. Watch the Dyersburg 503B’s inspection history, and don’t confuse it with the unrelated Wells Pharma of Houston.